Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients

  • Brochado, Óscar
  • Martínez, Isidoro
  • Medrano, Luz
  • González‑García, Juan
  • Jiménez‑Sousa, María Ángeles
  • Navarro Mercadé, Jordi
  • Berenguer, Juan
Coinfecció pel VIH/VHC; Sistema immunitari; Teràpia amb interferó, Coinfección por VIH/VHC; Sistema inmunitario; Terapia con interferón, HIV/HCV coinfection; Immune system; Interferon therapy, Objective To evaluate the impact of hepatitis C virus (HCV) elimination via interferon (IFN)-based therapy on gene expression profiles related to the immune system in HIV/HCV-coinfected patients. Methods We conducted a prospective study in 28 HIV/HCV-coinfected patients receiving IFN-based therapy at baseline (HIV/HCV-b) and week 24 after sustained virological response (HIV/HCV-f). Twenty-seven HIV-monoinfected patients (HIV-mono) were included as a control. RNA-seq analysis was performed on peripheral blood mononuclear cells (PBMCs). Genes with a fold-change (FC) ≥ 1.5 (in either direction) and false discovery rate (FDR) ≤ 0.05 were identified as significantly differentially expressed (SDE). Results HIV/HCV-b showed six SDE genes compared to HIV-mono group, but no significantly enriched pathways were observed. For HIV/HCV-f vs. HIV/HCV-b, we found 58 SDE genes, 34 upregulated and 24 downregulated in the HIV/HCV-f group. Of these, the most overexpressed were CXCL2, PDCD6IP, ATP5B, IGSF9, RAB26, and CSRNP1, and the most downregulated were IFI44 and IFI44L. These 58 SDE genes revealed two significantly enriched pathways (FDR < 0.05), one linked to Epstein-Barr virus infection and another related to p53 signaling. For HIV/HCV-f vs. HIV-mono group, we found 44 SDE genes that revealed 31 enriched pathways (FDR < 0.05) related to inflammation, cancer/cell cycle alteration, viral and bacterial infection, and comorbidities associated with HIV/HCV-coinfection. Five genes were overrepresented in most pathways (JUN, NFKBIA, PIK3R2, CDC42, and STAT3). Conclusion HIV/HCV-coinfected patients who eradicated hepatitis C with IFN-based therapy showed profound gene expression changes after achieving sustained virological response. The altered pathways were related to inflammation and liver-related complications, such as non-alcoholic fatty liver disease and hepatocellular carcinoma, underscoring the need for active surveillance for these patients., This study was supported by grants from Instituto de Salud Carlos III (ISCII; Grant Numbers PI20/00474 and PI17/00657 to JB, PI20/00507 and PI17/00903 to JGG, PI18CIII/00020 to AFR, and PI20CIII/00004 and PI17CIII/00003 to SR). The study was also funded by the RD16CIII/0002/0002 and RD16/0025/0017, and RD16/0025/0018 projects as part of the Plan Nacional R + D + I and co-funded by ISCIII- Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER). JB is an investigator from the Programa de Intensificación de la Actividad Investigadora en el Sistema Nacional de Salud (I3SNS), Ref. INT16/00100.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients

  • Brochado Kith, Óscar|||0000-0001-8372-2604
  • Martínez, Isidoro|||0000-0002-9949-9264
  • Berenguer, Juan|||0000-0001-8541-8200
  • Medrano, Luz María|||0000-0003-3717-5384
  • González García, Juan|||0000-0002-3652-002X
  • Jiménez-Sousa, María Ángeles|||0000-0002-1945-6169
  • Carrero, Ana
  • Hontañón Antoñana, Víctor|||0000-0003-3070-2647
  • Navarro, Jordi|||0000-0002-7187-0367
  • Guardiola Tey, Jose Maria|||0000-0001-5537-2600
  • Fernández-Rodríguez, Amanda|||0000-0002-5110-2213
  • Resino, Salvador|||0000-0001-8783-0450
Objective: To evaluate the impact of hepatitis C virus (HCV) elimination via interferon (IFN)-based therapy on gene expression profiles related to the immune system in HIV/HCV-coinfected patients. Methods: We conducted a prospective study in 28 HIV/HCV-coinfected patients receiving IFN-based therapy at baseline (HIV/HCV-b) and week 24 after sustained virological response (HIV/HCV-f). Twenty-seven HIV-monoinfected patients (HIV-mono) were included as a control. RNA-seq analysis was performed on peripheral blood mononuclear cells (PBMCs). Genes with a fold-change (FC) ≥ 1.5 (in either direction) and false discovery rate (FDR) ≤ 0.05 were identified as significantly differentially expressed (SDE). Results: HIV/HCV-b showed six SDE genes compared to HIV-mono group, but no significantly enriched pathways were observed. For HIV/HCV-f vs. HIV/HCV-b, we found 58 SDE genes, 34 upregulated and 24 downregulated in the HIV/HCV-f group. Of these, the most overexpressed were CXCL2, PDCD6IP, ATP5B, IGSF9, RAB26, and CSRNP1, and the most downregulated were IFI44 and IFI44L. These 58 SDE genes revealed two significantly enriched pathways (FDR < 0.05), one linked to Epstein-Barr virus infection and another related to p53 signaling. For HIV/HCV-f vs. HIV-mono group, we found 44 SDE genes that revealed 31 enriched pathways (FDR < 0.05) related to inflammation, cancer/cell cycle alteration, viral and bacterial infection, and comorbidities associated with HIV/HCV-coinfection. Five genes were overrepresented in most pathways (JUN, NFKBIA, PIK3R2, CDC42, and STAT3). Conclusion: HIV/HCV-coinfected patients who eradicated hepatitis C with IFN-based therapy showed profound gene expression changes after achieving sustained virological response. The altered pathways were related to inflammation and liver-related complications, such as non-alcoholic fatty liver disease and hepatocellular carcinoma, underscoring the need for active surveillance for these patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR

  • Vigón, Lorena
  • Vázquez-Morón, Sonia|||0000-0002-0977-741X
  • Berenguer, Juan|||0000-0001-8541-8200
  • González García, Juan|||0000-0002-3652-002X
  • Jiménez-Sousa, Ma Ángeles
  • Guardiola Tey, Jose Maria|||0000-0001-5537-2600
  • Crespo Casal, Manuel|||0000-0001-9016-0515
  • de los Santos Gil, Ignacio|||0000-0001-7073-5211
  • Von Wichmann, Miguel Ángel
  • Carrero, Ana
  • Yélamos, María Belén
  • Gómez, Julián
  • Resino, Salvador|||0000-0001-8783-0450
  • Martínez, Isidoro|||0000-0002-9949-9264
  • Miralles, Pilar
  • López, Juan Carlos
  • Parras, Francisco José
  • Padilla Ortega, Belén
  • Aldámiz-Echevarría Lois, Maria Teresa|||0000-0002-4374-6940
  • Tejerina, Francisco|||0000-0002-4136-3575
  • Diez, Cristina
  • Pérez Latorre, Leire|||0000-0001-9919-3778
  • Fanciulli, Chiara|||0000-0003-2175-9027
  • Gutiérrez, Isabel
  • Ramírez, Manuel|||0000-0003-0332-6973
  • Carretero, S.
  • Bellón, José-María|||0000-0002-8492-1565
  • Bermejo, Javier|||0000-0002-5241-2758
  • Hontañón Antoñana, Víctor|||0000-0003-3070-2647
  • Arribas, Jose|||0000-0002-7410-9450
  • Montes, María Luisa|||0000-0003-1748-813X
  • Bernardino, José Ignacio|||0000-0003-3501-8529
  • Pascual Pareja, J. Francisco
  • Zamora, Francisco
  • Peña, Jose M.
  • Arnalich Fernandez, Francisco|||0000-0003-2943-0373
  • Díaz, Marta
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Sanz, Jaime|||0000-0001-6934-4619
  • Bustinduy, M.J.
  • Iribarren, José Antonio
  • Rodríguez-Arrondo, F.
  • Eynde, E.Van den
  • Pérez, M.
  • Ribera, E.
  • Casado, José Luis|||0000-0002-7639-8591
  • Dronda, Fernando|||0000-0002-0443-5816
  • Moreno, A.
  • Pérez Elías, Mª Jesus|||0000-0001-5700-5257
  • Sanfrutos, M.A.
  • Moreno, S.
  • Quereda, Carmen
  • Arranz, A.
  • Casas Díaz, Encarna|||0000-0002-5901-6555
  • Miguel, J.de
  • Schroeder, S.
  • Vergas, J.
  • Téllez, M.J.
  • Vinuesa, D.
  • Muñoz, Lourdes
  • Hernández Quero, José
  • Ferrer, A.
  • Galindo Puerto, María José
  • Ortiz, L.
  • Ortega, Emilio|||0000-0002-2217-8905
  • Montero, M.
  • Blanes, M.
  • Cuellar, S.
  • Lacruz, José
  • Salavert, Miguel|||0000-0002-8571-2124
  • López-Aldeguer, J.
  • Pérez González, Gustavo|||0000-0001-9112-9042
  • Gaspar, G.
  • Yllescas, M.
  • Crespo, P.
  • Aznar, E.
  • Esteban, H.
The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who achieved sustained virological response (SVR) with peg-IFNα + ribavirin anti-HCV therapy. Plasma samples at baseline and week 24 after SVR were used to perform neutralization assays against five JFH1-based HCV recombinant viruses coding for E1 and E2 from genotypes 1a (H77), 1b (J4), 2a (JFH1), 3a (S52) and 4a (ED43). At baseline, the majority of plasma samples neutralized 1a, 1b, 2a, and 4a, but not 3a, genotypes. Twenty-four weeks following SVR, most neutralizing titers declined substantially. Furthermore, titers against 3a and 2a were not detected in many patients. Plasma samples with high HCV-nAb titers neutralized all genotypes, and the highest titers at the starting point correlated with the highest titers at week 24 after SVR. In conclusion, high titers of broad-spectrum HCV-nAbs were detected in HIV/HCV-coinfected individuals, however, those titers declined soon after SVR.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prevalence of hepatitis E infection in HIV/HCV-coinfected patients in Spain (2012-2014)

  • Vázquez-Morón, Sonia|||0000-0002-0977-741X
  • Berenguer, Juan|||0000-0001-8541-8200
  • González García, Juan|||0000-0002-3652-002X
  • Jiménez-Sousa, Ma Ángeles
  • Canorea, Isabel
  • Guardiola Tey, Jose Maria|||0000-0001-5537-2600
  • Crespo Casal, Manuel|||0000-0001-9016-0515
  • Quereda, Carmen
  • Sanz, José
  • Carrero, Ana
  • Hontañón Antoñana, Víctor|||0000-0003-3070-2647
  • Avellón, Ana|||0000-0003-4425-6350
  • Resino, Salvador|||0000-0001-8783-0450
Hepatitis E virus (HEV) has emerged as a relevant pathogen for HIV-infected patients. However, there is scarce data on HEV infection in HIV/HCV-coinfected individuals with advanced fibrosis, which seems to increase the risk of HEV infection and worsen the prognosis of liver disease. We aimed to determine the prevalence of anti-HEV antibodies, acute hepatitis E, resolved hepatitis E, and exposure to HEV in HIV/HCV-coinfected patients and to evaluate associations with clinical and epidemiological characteristics. We performed a cross-sectional study on 198 HIV/HCV-coinfected patients, 30 healthy controls and 36 HIV-monoinfected patients. We found a low concordance between techniques used for detection of anti-HEV antibodies (ELISA versus Immunoblot), particularly in HIV/HCV-coinfected patients. HIV/HCV-coinfected patients showed the highest prevalence of IgG against HEV, resolved hepatitis E, and exposure to HEV (19.2%, 17.2%, and 22.2% respectively). However, we did not find any samples positive for HEV-RNA nor significant differences between groups. Moreover, HIV/HCV-coinfected patients with CD4 T-cells <350 cells/mm had higher prevalence for anti-HEV IgG antibodies, resolved hepatitis E, and exposure to HEV than healthy controls or those with CD4 T-cells ≥ 350 cells/mm (p = 0.034, p = 0.035, and p = 0.053; respectively). In conclusion, HIV/HCV-coinfected patients in Spain have a high prevalence for IgG anti-HEV antibodies, resolved hepatitis E, and exposure to HEV; particularly patients with CD4+T-cells <350 cells/mm.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Human immunodeficiency virus/hepatits C virus coinfection in Spain, Elimination is feasible, but the burden of residual cirrhosis will be significant

  • Berenguer, Juan|||0000-0001-8541-8200
  • Jarrín, Inma|||0000-0002-7485-2252
  • Pérez Latorre, Leire|||0000-0001-9919-3778
  • Hontañón Antoñana, Víctor|||0000-0003-3070-2647
  • Vivancos-Gallego, María J.|||0000-0002-9373-6011
  • Navarro, Jordi|||0000-0002-7187-0367
  • Téllez, María Jesús
  • Guardiola Tey, Jose Maria|||0000-0001-5537-2600
  • Iribarren, José Antonio
  • Rivero-Juarez, Antonio|||0000-0002-5813-6889
  • Márquez, Manuel A.
  • Artero, Arturo|||0000-0002-7479-3408
  • Morano Amado, Luis Enrique|||0000-0002-0560-3260
  • de los Santos Gil, Ignacio|||0000-0001-7073-5211
  • Moreno, Javier Marta
  • Fariñas, Mª Carmen
  • Galindo Puerto, María José
  • Hernando, María Asunción
  • Montero, Marta|||0000-0002-3432-5394
  • Cifuentes, Carmen|||0000-0001-5521-4573
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Sanz, José Miguel
  • Domíngez, Lourdes
  • Ferrero, Óscar Luis
  • Fuente, Belén Pizarro de la
  • Herrero Rodríguez, Carmen
  • Reus, Sergio|||0000-0002-3320-9754
  • Hernández Quero, José
  • Gaspar Alonso-Vega, Gabriel|||0000-0002-7144-8959
  • Pérez-Martínez, Laura|||0000-0002-1384-024X
  • García, Coral Fernández
  • Force, Lluís
  • Veloso Esteban, Sergio|||0000-0001-7943-1169
  • Losa-García, Juan Emilio
  • Vilaró, Josep M.
  • Bernal, Enrique|||0000-0002-4041-0579
  • Arponen, Sari
  • Ortí, Amat-Joaquim|||0000-0003-3276-7276
  • Chocarro, Ángel
  • Teira, Ramón M.
  • Alonso, Gerardo
  • Silvariño, Rafael
  • Vegas, Ana
  • Geijo, Paloma
  • Bisbe, Josep
  • Esteban, Herminia
  • González García, Juan|||0000-0002-3652-002X
We assessed the prevalence of antibodies against hepatitis C virus (HCV-Abs) and active HCV infection in patients infected with human immunodeficiency virus (HIV) in Spain in 2016 and compared the results with those of similar studies performed in 2002, 2009, and 2015. Methods The study was performed in 43 centers during October-November 2016. The sample was estimated for an accuracy of 2% and selected by proportional allocation and simple random sampling. During 2016, criteria for therapy based on direct-acting antiviral agents (DAA) were at least significant liver fibrosis, severe extrahepatic manifestations of HCV, and high risk of HCV transmissibility. Results The reference population and the sample size were 38904 and 1588 patients, respectively. The prevalence of HCV-Abs in 2002, 2009, 2015, and 2016 was 60.8%, 50.2%, 37.7%, and 34.6%, respectively (P trend <.001, from 2002 to 2015). The prevalence of active HCV in 2002, 2009, 2015, and 2016 was 54.0%, 34.0%, 22.1%, and 11.7%, respectively (P trend <.001). The anti-HCV treatment uptake in 2002, 2009, 2015, and 2016 was 23.0%, 48.0%, 59.3%, and 74.7%, respectively (P trend <.001). In 2016, HCV-related cirrhosis was present in 7.6% of all HIV-infected individuals, 15.0% of patients with active HCV, and 31.5% of patients who cleared HCV after anti-HCV therapy. Conclusions Our findings suggest that with universal access to DAA-based therapy and continued efforts in prevention and screening, it will be possible to eliminate active HCV among HIV-infected individuals in Spain in the short term. However, the burden of HCV-related cirrhosis will continue to be significant among HIV-infected individuals.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients

  • Brochado, Óscar
  • Martínez, Isidoro
  • Medrano, Luz
  • González‑García, Juan
  • Jiménez‑Sousa, María Ángeles
  • Navarro Mercadé, Jordi
  • Berenguer, Juan
Coinfecció pel VIH/VHC; Sistema immunitari; Teràpia amb interferó, Coinfección por VIH/VHC; Sistema inmunitario; Terapia con interferón, HIV/HCV coinfection; Immune system; Interferon therapy, Objective To evaluate the impact of hepatitis C virus (HCV) elimination via interferon (IFN)-based therapy on gene expression profiles related to the immune system in HIV/HCV-coinfected patients. Methods We conducted a prospective study in 28 HIV/HCV-coinfected patients receiving IFN-based therapy at baseline (HIV/HCV-b) and week 24 after sustained virological response (HIV/HCV-f). Twenty-seven HIV-monoinfected patients (HIV-mono) were included as a control. RNA-seq analysis was performed on peripheral blood mononuclear cells (PBMCs). Genes with a fold-change (FC) ≥ 1.5 (in either direction) and false discovery rate (FDR) ≤ 0.05 were identified as significantly differentially expressed (SDE). Results HIV/HCV-b showed six SDE genes compared to HIV-mono group, but no significantly enriched pathways were observed. For HIV/HCV-f vs. HIV/HCV-b, we found 58 SDE genes, 34 upregulated and 24 downregulated in the HIV/HCV-f group. Of these, the most overexpressed were CXCL2, PDCD6IP, ATP5B, IGSF9, RAB26, and CSRNP1, and the most downregulated were IFI44 and IFI44L. These 58 SDE genes revealed two significantly enriched pathways (FDR < 0.05), one linked to Epstein-Barr virus infection and another related to p53 signaling. For HIV/HCV-f vs. HIV-mono group, we found 44 SDE genes that revealed 31 enriched pathways (FDR < 0.05) related to inflammation, cancer/cell cycle alteration, viral and bacterial infection, and comorbidities associated with HIV/HCV-coinfection. Five genes were overrepresented in most pathways (JUN, NFKBIA, PIK3R2, CDC42, and STAT3). Conclusion HIV/HCV-coinfected patients who eradicated hepatitis C with IFN-based therapy showed profound gene expression changes after achieving sustained virological response. The altered pathways were related to inflammation and liver-related complications, such as non-alcoholic fatty liver disease and hepatocellular carcinoma, underscoring the need for active surveillance for these patients., This study was supported by grants from Instituto de Salud Carlos III (ISCII; Grant Numbers PI20/00474 and PI17/00657 to JB, PI20/00507 and PI17/00903 to JGG, PI18CIII/00020 to AFR, and PI20CIII/00004 and PI17CIII/00003 to SR). The study was also funded by the RD16CIII/0002/0002 and RD16/0025/0017, and RD16/0025/0018 projects as part of the Plan Nacional R + D + I and co-funded by ISCIII- Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER). JB is an investigator from the Programa de Intensificación de la Actividad Investigadora en el Sistema Nacional de Salud (I3SNS), Ref. INT16/00100.